Lobbying Relationship

Client

Roivant Sciences, Inc.

More records

Lobbying firm

AMERICAN CONTINENTAL GROUP

More records

  • Drug Pricing. Innovation Issues.

Duration: to

General Issues: Pharmacy

Spending: about $270,000 (But it's complicated. Here's why.)

Agencies lobbied since 2017: House of Representatives, U.S. Senate, Food & Drug Administration (FDA)

Related Foreign Entities: Roivant Sciences Ltd. (Hamilton, BER); contribution to lobbying: $0; ownership 100%; Roivant Sciences Holdings Ltd. (London, WC1R 4JS, GBR); contribution to lobbying: $0; ownership 100%

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Manus Cooney Staff Director & Chief Counsel, Senate Judiciary Committee
David Urban Chief of Staff, Senator Arlen Specter
Julie Philp LD, Rep. John Campbell; LA/Senior LA, Rep. Gil Gutknecht; LA and Scheduler, Rep. Michael Burgess; LA, Scheduler, Rep. Connie Morella; LA, Ileana Ros-Lehtinen
Mary O'Dea Ahearn n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q1 Report
Q4 Report
Q3 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page